Maria R. Baer
Leukemia Section
Dept. of Medicine
Roswell Park Cancer Institute
Elm and Carlton Sts.
USA
Name/email consistency: high
- Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Baer, M.R., George, S.L., Dodge, R.K., O'Loughlin, K.L., Minderman, H., Caligiuri, M.A., Anastasi, J., Powell, B.L., Kolitz, J.E., Schiffer, C.A., Bloomfield, C.D., Larson, R.A. Blood (2002)
- Detection of minimal residual disease in acute myeloid leukemia. Baer, M.R. Curr. Oncol. Rep (2002)
- High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Baer, M.R., Stewart, C.C., Dodge, R.K., Leget, G., Sulé, N., Mrózek, K., Schiffer, C.A., Powell, B.L., Kolitz, J.E., Moore, J.O., Stone, R.M., Davey, F.R., Carroll, A.J., Larson, R.A., Bloomfield, C.D. Blood (2001)









